BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 33350681)

  • 1. Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody.
    Akce M; Liu Y; Zakka K; Martini DJ; Draper A; Alese OB; Shaib WL; Wu C; Wedd JP; Sellers MT; Bilen MA; El-Rayes BF
    Am J Clin Oncol; 2021 Feb; 44(2):74-81. PubMed ID: 33350681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
    Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
    BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma.
    Lanza E; Masetti C; Messana G; Muglia R; Pugliese N; Ceriani R; Lleo de Nalda A; Rimassa L; Torzilli G; Poretti D; D'Antuono F; Politi LS; Pedicini V; Aghemo A;
    PLoS One; 2020; 15(6):e0232371. PubMed ID: 32555707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab.
    Kim N; Yu JI; Park HC; Yoo GS; Choi C; Hong JY; Lim HY; Lee J; Choi MS; Lee JE; Kim K
    Cancer Immunol Immunother; 2021 Jun; 70(6):1593-1603. PubMed ID: 33231725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
    Bilen MA; Martini DJ; Liu Y; Shabto JM; Brown JT; Williams M; Khan AI; Speak A; Lewis C; Collins H; Kissick HT; Carthon BC; Akce M; Shaib WL; Alese OB; Pillai RN; Steuer CE; Wu CS; Lawson DH; Kudchadkar RR; El-Rayes BF; Ramalingam SS; Owonikoko TK; Harvey RD; Master VA
    Oncologist; 2020 Mar; 25(3):e528-e535. PubMed ID: 32162807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study.
    Cortellini A; Bozzetti F; Palumbo P; Brocco D; Di Marino P; Tinari N; De Tursi M; Agostinelli V; Patruno L; Valdesi C; Mereu M; Verna L; Lanfiuti Baldi P; Venditti O; Cannita K; Masciocchi C; Barile A; McQuade JL; Ficorella C; Porzio G
    Sci Rep; 2020 Jan; 10(1):1456. PubMed ID: 31996766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma.
    Iritani S; Imai K; Takai K; Hanai T; Ideta T; Miyazaki T; Suetsugu A; Shiraki M; Shimizu M; Moriwaki H
    J Gastroenterol; 2015 Mar; 50(3):323-32. PubMed ID: 24817668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of muscle mass on survival of patients with hepatocellular carcinoma after liver transplantation beyond the Milan criteria.
    Beumer BR; van Vugt JLA; Sapisochin G; Yoon P; Bongini M; Lu D; Xu X; De Simone P; Pintore L; Golse N; Nowosad M; Bennet W; Tsochatzis E; Koutli E; Abbassi F; Claasen MPAW; Merli M; O'Rourke J; Gambato M; Benito A; Majumdar A; Tan EK; Ebadi M; Montano-Loza AJ; Berenguer M; Metselaar HJ; Polak WG; Mazzaferro V; IJzermans JNM;
    J Cachexia Sarcopenia Muscle; 2022 Oct; 13(5):2373-2382. PubMed ID: 36622940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors.
    Liu M; Jin Q; Wang H; Li Y
    Front Immunol; 2024; 15():1396927. PubMed ID: 38690276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma.
    Chen BB; Liang PC; Shih TT; Liu TH; Shen YC; Lu LC; Lin ZZ; Hsu C; Hsu CH; Cheng AL; Shao YY
    Eur Radiol; 2023 Jan; 33(1):512-522. PubMed ID: 35864351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma.
    Sellers CM; Uhlig J; Ludwig JM; Pollak JS; Taddei TH; Stein SM; Lim JK; Kim HS
    Cancer Med; 2021 Aug; 10(16):5395-5404. PubMed ID: 34318618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
    BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preablation neutrophil-to-lymphocyte ratio as an independent prognostic factor in locally advanced hepatocellular carcinoma patients following radiofrequency ablation.
    Tan W; Sun W; Li X; Zhao L; Wang C; Zang A; Kong X
    J Cancer Res Ther; 2018 Jan; 14(1):84-89. PubMed ID: 29516965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline Sarcopenia is Associated with Lack of Response to Therapy, Liver Decompensation and High Mortality in Hepatocellular Carcinoma Patients.
    Badran H; Elsabaawy MM; Ragab A; Aly RA; Alsebaey A; Sabry A
    Asian Pac J Cancer Prev; 2020 Nov; 21(11):3285-3290. PubMed ID: 33247686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of the skeletal muscle index and systemic inflammatory index in patients with lymph node-positive breast cancer after radical mastectomy.
    Tang R; Deng JP; Zhang L; Zhang WW; Sun JY; Chi F; Zhang J; Wu SG; He ZY
    BMC Cancer; 2022 Mar; 22(1):234. PubMed ID: 35241010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma.
    Takada H; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Tsuchiya K; Yasui Y; Tamaki N; Takaura K; Komiyama Y; Higuchi M; Kubota Y; Wang W; Okada M; Enomoto N; Izumi N
    PLoS One; 2018; 13(6):e0198812. PubMed ID: 29912922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment Inflammation-Based Markers Predict Survival Outcomes in Patients with Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation.
    Chu MO; Shen CH; Chang TS; Xu HW; Yen CW; Lu SN; Hung CH
    Sci Rep; 2018 Nov; 8(1):16611. PubMed ID: 30413724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study".
    Mardian Y; Yano Y; Ratnasari N; Choridah L; Wasityastuti W; Setyawan NH; Hayashi Y
    BMC Gastroenterol; 2019 Dec; 19(1):229. PubMed ID: 31888500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study.
    Feliciano EMC; Kroenke CH; Meyerhardt JA; Prado CM; Bradshaw PT; Kwan ML; Xiao J; Alexeeff S; Corley D; Weltzien E; Castillo AL; Caan BJ
    JAMA Oncol; 2017 Dec; 3(12):e172319. PubMed ID: 28796857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stratified neutrophil-to-lymphocyte ratio accurately predict mortality risk in hepatocellular carcinoma patients following curative liver resection.
    Huang GQ; Zhu GQ; Liu YL; Wang LR; Braddock M; Zheng MH; Zhou MT
    Oncotarget; 2016 Feb; 7(5):5429-39. PubMed ID: 26716411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.